» Articles » PMID: 24481996

Epidemiology and Etiopathogenesis of Pituitary Adenomas

Overview
Journal J Neurooncol
Publisher Springer
Date 2014 Feb 1
PMID 24481996
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Pituitary adenomas are usually benign monoclonal tumours presenting either due to hypersecretion of pituitary hormones, and/or due to local space occupying effects and hyposecretion of some or all of the pituitary hormones. Some pituitary adenomas cause prominent symptoms, while others may result in slowly developing, insidious, non-specific complains delaying accurate diagnosis, with a third group remaining symptomless and recognised only incidentally. Therefore, it is a challenge to accurately determine the prevalence and incidence of pituitary adenomas in the general population. The vast majority of pituitary adenomas occur sporadically, but familial cases are now increasingly recognised. Hereditary predisposition, somatic mutations and endocrine factors were shown to have a pathophysiologic role in the initiation and progression of pituitary adenomas, which interestingly almost always remain benign. Here, we summarize the available epidemiological data and the known pathogenesis of the pituitary adenomas.

Citing Articles

A rare case of double pituitary prolactinomas: the diagnostic application of intraoperative ultrasonography and DNA methylation markers.

Reese J, Zervos T, Rock J, Tabbarah A, Noushmehr H, Herrgott G Arch Endocrinol Metab. 2025; 68(Spec Issue):e230506.

PMID: 39876960 PMC: 11771751. DOI: 10.20945/2359-4292-2023-0506.


Assessment of the initial results of pituitary tumor registry at a tertiary hospital of Iran: 2009-2022.

Mohseni S, Mirdamadi N, Mossavarali S, Mohajeri-Tehrani M, Pejman Sani M J Diabetes Metab Disord. 2024; 23(2):2143-2149.

PMID: 39610525 PMC: 11599527. DOI: 10.1007/s40200-024-01481-9.


Therapeutical Usefulness of PD-1/PD-L1 Inhibitors in Aggressive or Metastatic Pituitary Tumours.

Lopes-Pinto M, Lacerda-Nobre E, Silva A, Marques P Cancers (Basel). 2024; 16(17).

PMID: 39272895 PMC: 11394371. DOI: 10.3390/cancers16173033.


Feasibility of Early Surgical Treatment for Adolescent Patients with Prolactinoma: A Case Report and Literature Review.

Tsai Y, Li C, Wang Y, Chen S Medicina (Kaunas). 2024; 60(8).

PMID: 39202626 PMC: 11356365. DOI: 10.3390/medicina60081345.


Outcome of non-functioning ACTH pituitary tumors: silent does not mean indolent.

Sahakian N, Goetz L, Appay R, Graillon T, Raingeard I, Piazzola C Pituitary. 2024; 27(5):644-653.

PMID: 38995473 DOI: 10.1007/s11102-024-01428-6.


References
1.
Costello R . Subclinical Adenoma of the Pituitary Gland. Am J Pathol. 2009; 12(2):205-216.1. PMC: 1911070. View

2.
Ueno M, Inano H, Onoda M, Murase H, Ikota N, Kagiya T . Modification of mortality and tumorigenesis by tocopherol-mono-glucoside (TMG) administered after X irradiation in mice and rats. Radiat Res. 2009; 172(4):519-24. DOI: 10.1667/RR1695.1. View

3.
Thakker R . Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010; 24(3):355-70. DOI: 10.1016/j.beem.2010.07.003. View

4.
Leontiou C, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S . The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008; 93(6):2390-401. DOI: 10.1210/jc.2007-2611. View

5.
Hunter J, Skelly R, Aylwin S, Geddes J, Evanson J, Besser G . The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol. 2003; 148(2):203-11. DOI: 10.1530/eje.0.1480203. View